Penpulimab (Anniko)

Note: Penpulimab is approved in China, but does not appear to have a brand name at this time.

Mechanism of action

PD-1 inhibitor

Diseases for which it is used

• Hodgkin lymphoma

History of changes in NMPA indication

• 8/5/2021: Approved for treatment of patients with relapsed or refractory (“r/r”) classic Hodgkin’s lymphoma (“cHL”) after at least second-line systemic chemotherapy treatment.

Also known as

• Code name: AK105